BioView develops, manufactures, and markets automated cell-imaging and analysis solutions for use in cytology, cytogenetic, pathology, clinical, and research laboratories. The company's products include a wide range of FDA-cleared clinical applications as well as web review and analysis solutions. BioView's proprietary imaging, analysis, and review technology automatically controls fully motorized fluorescent and bright-field microscopes equipped with high-resolution cameras. This automates the review, analysis, and reporting processes and reduces laboratories' turnaround time on labor-intensive tests. BioView's DUET imaging and analysis platform has received FDA clearance for several FISH applications for cancer detection and diagnosis and detection of genetic aberrations. BioView products have CE marking, as well as a Korean, Australian, and Thai FDA approval. The company is continually expanding its regulatory approval reach to additional countries. The company is currently developing and plans to market its proprietary, self-developed test for noninvasive early detection of lung cancer, combining a biological test kit and BioView's unique Target FISH application.